The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
about
Computer-based prediction of the drug proarrhythmic effect: problems, issues, known and suspected challengesThe Simcyp population-based ADME simulatorA comprehensive model for the humoral coagulation network in humans.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Clinical pharmacology--providing tools and expertise for translational medicineA systems approach to designing effective clinical trials using simulations.CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models.Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor.Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power.Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin.
P2860
Q26861453-755FA599-C18E-44F1-A2CC-F06663406B9DQ28308225-7D578E19-8F72-4315-A9E3-706B4E5A931DQ34986144-41DC350E-1D9E-4933-91F2-89767EE119EDQ35560052-D8584CF0-6059-46C5-8BFC-1301899B81DBQ36475190-4B636902-0F5B-4458-88CD-653AEB84776BQ37077687-4E23815F-08B3-431E-BB4D-BBB8B62E303FQ37106741-FB4014F4-5A1F-4CC9-9A46-3B588213A156Q37325589-3C0B1223-B7B1-4F76-A3FB-0C240CBD2A58Q37394474-F01B60B4-7AF3-4FDF-9551-083DDD730CDBQ37521097-22D1F7F5-1070-441C-A3BC-604401F38D09Q37824590-151D8DE1-0937-43BF-A08C-370F294C10F6Q38014312-42E0EAC3-9E3D-4D20-9299-39BEDF81EFD5Q38181565-A7C7F203-FEF1-4654-8C00-8D4B2DD2EA37Q38798449-85D56B81-58AF-4ABD-94F4-3E92213D1450Q38893410-C643804B-2215-44AD-923C-74EA3E8A6563Q41150870-D3DB9E49-5A53-42F5-863C-1E68C325778CQ44537853-A3A853CD-7C26-44EF-998A-B6A9B24B0DEEQ45759815-4FDCBE9C-8E8F-4119-B629-C5A818105109Q52658558-AE38FDE3-E550-438B-BEAB-1786C0C49305
P2860
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The use of mechanistic DM-PK-P ...... C9 and warfarin as an example.
@en
type
label
The use of mechanistic DM-PK-P ...... C9 and warfarin as an example.
@en
prefLabel
The use of mechanistic DM-PK-P ...... C9 and warfarin as an example.
@en
P2093
P2860
P1476
The use of mechanistic DM-PK-P ...... C9 and warfarin as an example.
@en
P2093
Amin Rostami-Hodjegan
Gemma L Dickinson
Geoffrey T Tucker
Martin S Lennard
P2860
P356
10.1111/J.1365-2125.2007.02850.X
P407
P577
2007-02-12T00:00:00Z